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测指标。我们的结果表明过表达 Mindin 后肠癌细胞 CMT93 和 CT26.WT 增殖
和侵袭受到了明显抑制，而干扰了 Mindin 之后明显促进了肿瘤细胞的增殖和侵
袭，其功能主要是通过 ERK、c-Fos 通路和细胞周期进行调控。进一步的研究发
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                           Abstract 
Colorectal cancer (CRC) is one of the most common cancers worldwide. The 
mechanism of CRC initiation has been analyzed in detail. However, solid tumors are 
not simply clones of cancer cells. Instead, they are abnormal organs that are composed 
of multiple cell types and extracellular matrix (ECM). The ECM, one component of 
the tumor microenvironment, contains various peptide factors and metabolites that are 
responsible for transmitting environmental signals to cells, and these signals 
essentially affect all aspects of a cell’s life, including its proliferation, differentiation 
and death. However, the identity of the ECM protein that is involved in CRC 
development and progression is not yet completely clear. 
Mindin is a member of the Mindin-F-spondin family of secreted ECM proteins 
which is important in both innate and adaptive immunity. However, the role of 
Mindin during colon cancer development remains undefined.   
Mindin is expressed in multiple organs, including the gut, peyer's lymph nodes 
spleen, lungs, and heart tissues. We found that the mRNA and protein of Mindin were 
significantly decreased in colon cancer tissue serum compared with normal tissue. 
Additional, the Mindin levels were significantly decreased in colorectal cancer 
patients when compared with healthy controls. This decreased level of Mindin was 
found to be significantly associated with the early stages of disease, rate of survival 
and recurrence, and its increase was identified as a predictor for chemotherapy 
response in the partial response group. Our data demonstrated that overexpression of 
Mindin suppressed cell proliferation in both of CMT93 and CT26.WT colon cancer 
cell lines, while the silencing of Mindin promoted in vitro cell proliferation via the 
ERK and c-Fos pathways and cell cycle control. Furthermore, the overexpression of 
Mindin significantly suppressed in vivo tumor growth in both the subcutaneous 
transplantation and AOM/DSS-induced CAC models. The silencing of Mindin 
consistently reversed these in vivo results. Mindin plays a novel tumor suppressive 
function during colon cancer development. Our results suggest that Mindin can be 
exploited as a potential therapeutic target for CRC.  
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 第一章  前  言 
 第一节  肠癌的研究进展 
1.1.1 概述 
在世界范围内，大肠癌(colorectal cancer，CRC)发病率在恶性肿瘤中排第三
位，在癌症引起死亡病例中排第四位，每年有 100 多万的大肠癌新发病例[1, 2]。
根据其病因学分类，有约 20%的大肠癌患者有家族遗传史[3]，包括家族性腺瘤性
息肉病 (famili aladenomatous polyposis，FAP)及遗传性非息肉病性大肠癌 [4] 



































离、端粒稳定性和 DNA 损伤反应的缺陷所导致[11, 12]，然而导致 CIN 的全部基因
尚未完全发现。在 CIN 肿瘤中典型核型畸形与特殊肿瘤抑制基因和致癌基因特
征突变的累积同时存在，这是大肠癌发生、发展的关键途径。1990 年 Fearon 和









生物体内引发癌症，而当突变的 K-ras 与 APC 的同时突变时才能促进肿瘤的发
生[16, 17]。 
MSI 则是由于 DNA 错配修复缺失引起的高突变表型，错配修复基因
MMR(mismatch repair gene)系统功能失活引起 MSI，导致一系列基因改变是其主
要发病机制[18, 19]。目前已确定这个系统包括 MLH1、PMS2、PMS1、MSH6 等基
因[20-22]。受 MSI 影响的其他基因也被确定，包括编码细胞增殖调节因子 [23, 
24](GRB1、TCF-4、WISP3、activin receptor-2、insulin-like growth factor-2 receptor、
axin-2、CDX)、细胞周期或细胞凋亡[25, 26](BAX、caspase-5、RIZ、BCL-10、PTEN、
hG4-1、FAS)和 DNA 修复(MBD-4、BLM、CHK1、MLH3、RAD50、MSH2、
MSH3、MSH6)等[27, 28]。值得注意的是，除了 MLH1 基因，每个个体的错配修复
基因都包含 A7 单核苷酸重复。因此，随着系统成员缺失的积累，MMR 系统功
能缺陷就越来越严重。但是，在所有肿瘤中这些基因的双等位基因失活尚无报道，
因此，目前这些位点的突变有多少是有意义的突变尚不清楚，或者说有些只单纯
是 MSI 的标记。以往关于 MSI 的研究主要都集中在遗传性大肠癌，如 HNPCC
及 Lynch 综合征上，但实际上只有 3%与 Lynch 综合征有关，而有 12%～17%的



























错配修复基因 hMLH1、hMSH2、p16、p14、MYF、MDR1 和 E-cadherin 等[35, 36] 。
研究发现，MSI 相关散发性大肠癌的形成过程也涉及 CIMP[37]。hMLH1、p16、








细胞黏附分子(EpCAM，也可称为 ESA)和富含亮氨酸重复单位的 G 蛋白偶联受
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